CN108341807B - Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof - Google Patents

Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof Download PDF

Info

Publication number
CN108341807B
CN108341807B CN201810129153.4A CN201810129153A CN108341807B CN 108341807 B CN108341807 B CN 108341807B CN 201810129153 A CN201810129153 A CN 201810129153A CN 108341807 B CN108341807 B CN 108341807B
Authority
CN
China
Prior art keywords
piperazine
amide compound
product
piperazine amide
benzodioxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810129153.4A
Other languages
Chinese (zh)
Other versions
CN108341807A (en
Inventor
刘志平
闫瑞
朱家伟
岳梦琳
田荣威
李勇强
吴孝婧
秦洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pingdingshan University
Original Assignee
Pingdingshan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pingdingshan University filed Critical Pingdingshan University
Priority to CN201810129153.4A priority Critical patent/CN108341807B/en
Publication of CN108341807A publication Critical patent/CN108341807A/en
Application granted granted Critical
Publication of CN108341807B publication Critical patent/CN108341807B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of non-steroidal anti-inflammatory drugs, and particularly relates to a piperazine amide compound containing benzodioxane skeleton, and a preparation method and application thereof. The piperazine amide compound containing the benzodioxane skeleton is prepared by mixing 1, 4-benzodioxane formylhydrazine, potassium hydroxide and methanol, dripping carbon disulfide in an ice water bath, performing reflux reaction, spin-drying a solvent, adding water, filtering, and acidifying filtrate to obtain a product a; mixing a substitute of piperazine, triethylamine and dichloromethane, dropwise adding chloroacetyl chloride in an ice water bath, reacting, and filtering to obtain a product b; and mixing the product a, the product b, potassium hydroxide and methanol, and reacting to obtain the catalyst. The piperazine amide compound containing the benzodioxane skeleton is simple to synthesize, convenient to purify, high in yield and good in stability in air; the preparation method is simple and feasible, and is suitable for industrial production. In addition, the invention has better anti-inflammatory activity and can be used for preparing non-steroidal anti-inflammatory drugs.

Description

Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof
Technical Field
The invention belongs to the technical field of non-steroidal anti-inflammatory drugs, and particularly relates to a piperazine amide compound containing benzodioxane skeleton, and a preparation method and application thereof.
Background
Inflammation is a self-defense mechanism of the body against infection, and is mainly manifested by red swelling, edema, pain, fever, and the like. Non-steroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, ibuprofen, naproxen, and fenbufen, are the first-line drugs most commonly used clinically to treat inflammation. According to incomplete statistics, 1 hundred million people use the medicine all over the world. The problem of adverse reactions and side effects of NSAIDs is also prominent as first-line drugs for anti-inflammatory and analgesic use. Therefore, the research and development of the non-steroidal anti-inflammatory drug with high efficiency and small side effect has important significance.
The benzodioxan backbone has a very broad biological activity, and molecular design and synthetic process studies of this class of compounds have been the focus of interest, such as those disclosed in Sun, J.; Wang, S.; Sheng, G.H.; L ian, Z.M.; L iu, H.Y.; Zhu, H. L. bioorg.Med.Chem.2016,24, 5626. 5632. Quaglia, W.; Piergentili, A.; Del Bello, F.; Farande, Y.; Giannella, M.; Pigini, M.; Rafaani, G.; Carrieri, A.; Amantini, C.; L mediali, R.; Santoni G.; Poesi E.; E. L eonardi, A.J.2008. J.2008. 9, J.59. J.9, J.9. Shield Bulll., U.S.J.487 to No. J.9, and U.S.A. J.A. 5, and No. J.11, J.P.P.P.A. D. 5, to disclose the use of the aforementioned steroid.
Piperazine derivatives have attracted much attention because of their various biological activities, such as Khaled, r.r., abdellifa, a.m., Edward, e.g., anti-cancer, anti-bacterial, anti-depression, anti-hypertension, anti-inflammatory and analgesic activities, such as L et.2014, 24, 5015-.
By utilizing the active framework splicing principle, the synergistic anti-inflammatory activity of the benzodioxane framework and the piperazine framework is exerted, the piperazine derivative based on the benzodioxane framework is synthesized, and the anti-inflammatory activity of the piperazine derivative is researched, so that the piperazine derivative has a good application prospect. No reports on piperazine amide compounds containing a benzodioxane skeleton have been found.
Disclosure of Invention
The invention aims to provide a piperazine amide compound containing a benzodioxane skeleton, which has strong anti-inflammatory activity and good stability; the invention also provides a preparation method and application thereof.
The piperazine amide compound containing the benzodioxane skeleton has the following structural formula:
Figure BDA0001574407100000021
wherein R is one of the following structures:
Figure BDA0001574407100000022
the preparation method of the piperazine amide compound containing the benzodioxane skeleton comprises the following steps:
(1) mixing 1, 4-benzodioxan formyl hydrazine, potassium hydroxide and methanol, dripping carbon disulfide in an ice-water bath, performing reflux reaction, spin-drying a solvent, adding water, filtering, and acidifying filtrate to obtain a product a;
(2) mixing a substitute of piperazine, triethylamine and dichloromethane, dropwise adding chloroacetyl chloride in an ice water bath, reacting, and filtering to obtain a product b;
(3) and mixing the product a, the product b, potassium hydroxide and methanol, and reacting to obtain the piperazine amide compound containing the benzodioxane skeleton.
Wherein:
in the step (1), the dosage ratio of the 1, 4-benzodioxan formyl hydrazine, the potassium hydroxide, the carbon disulfide and the methanol is 1:1.2-1.5:10:5-7, wherein the 1, 4-benzodioxan formyl hydrazine, the potassium hydroxide and the carbon disulfide are counted in millimole, and the methanol is counted in milliliter.
In the step (1), the dropping time of the carbon disulfide is 15-20 minutes.
In the step (1), the reflux reaction time is 8-10 hours.
In the step (2), the dosage ratio of the substituent of piperazine, chloracetyl chloride, triethylamine and dichloromethane is 1:1.2-1.5:1.2-1.5:4, wherein the substituent of piperazine, chloracetyl chloride and triethylamine are calculated by millimole, and the dichloromethane is calculated by milliliter.
In the step (2), the substitute of piperazine is one of o-methoxyphenylpiperazine, m-methoxyphenylpiperazine, p-methoxyphenylpiperazine, o-chlorophenylpiperazine, m-chlorophenylpiperazine, o-fluorophenylpiperazine, 2-pyridylpiperazine or m-trifluoromethylphenylpiperazine.
In the step (2), the dripping time of the chloracetyl chloride is 3-5 minutes; the reaction time is 10-12 hours.
In the step (3), the using amount ratio of the product a to the product b to the potassium hydroxide to the methanol is 1:1:1.5:8, wherein the product a, the product b and the potassium hydroxide are calculated by millimoles, and the methanol is calculated by milliliter; the reaction time is 4-6 hours.
The piperazine amide compound containing the benzodioxane skeleton is used for preparing the non-steroidal anti-inflammatory drug.
The reaction equation of the present invention is as follows:
Figure BDA0001574407100000031
wherein R is one of the following structures:
Figure BDA0001574407100000032
the invention has the following beneficial effects:
the piperazine amide compound containing the benzodioxane skeleton is simple to synthesize, 1, 4-benzodioxane formylhydrazine and carbon disulfide are subjected to cyclization reaction to obtain a benzodioxane sulfydryl derivative, acyl chloride with higher activity in chloroacetyl chloride and unsubstituted amino in the monosubstituted piperazine derivative are subjected to nucleophilic substitution reaction to obtain a piperazine amide intermediate, and α -chloride in the piperazine amide intermediate is subjected to nucleophilic substitution reaction with sulfydryl in the benzodioxane sulfydryl derivative to obtain the piperazine amide compound containing the benzodioxane skeleton.
Detailed Description
The present invention is further described below with reference to examples.
Example 1
Preparation of 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (2-methoxyphenyl) piperazine) ethanone, its molecular formula is:
Figure BDA0001574407100000041
(1) dissolving 10mmol of 1, 4-benzodioxan formyl hydrazine and 12mmol of potassium hydroxide in 50m L methanol, dropwise adding 100mmol of carbon disulfide in an ice water bath, controlling the dropwise addition within 15 minutes, carrying out reflux reaction for 8 hours after the carbon disulfide is dropwise added, spin-drying a solvent, adding water for dissolution, filtering, adding hydrochloric acid into a filtrate for acidification, and filtering to obtain a product a;
(2) dissolving 8mmol of o-methoxyphenyl piperazine and 9.6mmol of triethylamine in 32m L dichloromethane, slowly dropwise adding 9.6mmol of chloroacetyl chloride under the ice bath condition, controlling the dropwise adding within 3 minutes, stirring under the ice bath condition for reaction for 10 hours, and filtering to obtain a product b;
(3)4mmol of the product a, 4mmol of the product b and 6mmol of potassium hydroxide are dissolved in 32m L methanol, stirred at normal temperature, reacted for 4 hours and then filtered to obtain the 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (2-methoxyphenyl) piperazine) ethanone.
The compound is verified by nuclear magnetism, mass spectrum and element analysis, and the result shows that the compound has a correct structure, and the data is as follows:
nuclear magnetism1H NMR(400MHz,CDCl3):3.08(s,2H),3.13(s,2H),3.78(s,2H),3.86(s,2H),3.89(s,3H),4.29-4.33(m,4H),4.43(s,2H),6.89-7.08(m,5H),7.49-7.52(m,2H)。
Mass spectrum ESI-MS: 959.33([2M + Na)]+)。
Elemental analysis anal.calcd for C23H24N4O5S:C,58.96;H,5.16;N,11.96.Found:C,59.15;H,5.13;N,12.01%。
Example 2
Preparation of 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (3-methoxyphenyl) piperazine) ethanone, its molecular formula is:
Figure BDA0001574407100000042
(1) dissolving 10mmol of 1, 4-benzodioxan formyl hydrazine and 13mmol of potassium hydroxide in 60m L methanol, dropwise adding 100mmol of carbon disulfide in an ice water bath, completing dropwise addition within 18 minutes, performing reflux reaction for 9 hours after completing dropwise addition of the carbon disulfide, spin-drying a solvent, adding water for dissolution, filtering, adding hydrochloric acid into filtrate for acidification, and filtering to obtain a product a;
(2)8mmol of m-methoxyphenyl piperazine and 11mmol of triethylamine are dissolved in 32m L dichloromethane, 11mmol of chloroacetyl chloride is slowly dripped under the ice bath condition, the dripping is finished within 4 minutes, the mixture is stirred and reacts for 11 hours under the ice bath condition, and the product b is obtained after filtration;
(3)4mmol of the product a, 4mmol of the product b, 6mmol of potassium hydroxide are dissolved in 32m L methanol, reacted for 5 hours at normal temperature and filtered to obtain the 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thioketone) -1- (4- (3-methoxyphenyl) piperazine) ethanone.
The compound is verified by nuclear magnetism, mass spectrum and element analysis, the result shows that the structure is correct, and the data is as follows:
nuclear magnetism1H NMR(400MHz,CDCl3):3.16(t,2H),3.29(s,2H),3.81(s,5H),3.88(s,2H),4.29-4.34(m,4H),4.39(s,2H),6.50-6.59(m,3H),6.95(d,1H),7.21(t,1H),7.48-7.52(m,2H)。
Mass spectrum ESI-MS: 491.33([ M + Na ]]+)。
Elemental analysis anal.calcd for C23H24N4O5S:C,58.96;H,5.16;N,11.96.Found:C,58.78;H,5.14;N,11.98%。
Example 3
Preparation of 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (4-methoxyphenyl) piperazine) ethanone, its molecular formula is:
Figure BDA0001574407100000051
(1) dissolving 10mmol of 1, 4-benzodioxan formyl hydrazine and 15mmol of potassium hydroxide in 70m L methanol, dropwise adding 100mmol of carbon disulfide in an ice water bath, completing dropwise addition within 20 minutes, performing reflux reaction for 10 hours after completing dropwise addition of the carbon disulfide, spin-drying a solvent, adding water for dissolution, filtering, adding hydrochloric acid into filtrate for acidification, and filtering to obtain a product a;
(2)8mmol of p-methoxyphenyl piperazine and 12mmol of triethylamine are dissolved in 32m L dichloromethane, 12mmol of chloroacetyl chloride is slowly dripped under the ice bath condition, the dripping is finished within 5 minutes, the mixture is stirred and reacts for 12 hours under the ice bath condition, and the product b is obtained after filtration;
(3)4mmol of the product a, 4mmol of the product b, 6mmol of potassium hydroxide are dissolved in 32m L methanol, reacted for 6 hours at normal temperature and filtered to obtain the 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thioketone) -1- (4- (4-methoxyphenyl) piperazine) ethanone.
The compound is verified by nuclear magnetism, mass spectrum and element analysis, the result shows that the structure is correct, and the data is as follows:
nuclear magnetism1H NMR(400MHz,CDCl3):3.07(t,2H),3.12(t,2H),3.75(t,2H),3.78(s,3H),3.82(t,2H),4.29-4.34(m,4H),4.41(s,2H),6.84-6.96(m,5H),7.48-7.52(m,2H)。
Mass Spectrometry ESI-MS:491.25([ M + Na ]]+)。
Elemental analysis anal.calcd for C23H24N4O5S:C,58.96;H,5.16;N,11.96.Found:C,59.20;H,5.14;N,11.99%。
Example 4
Preparation of 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (2-chlorophenyl) piperazine) ethanone of the formula:
Figure BDA0001574407100000061
the o-methoxyphenylpiperazine was changed to o-chlorophenylpiperazine in example 1, and the rest of the procedure was the same as in example 1, to give 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (2-chlorophenyl) piperazine) ethanone.
The compound is verified by nuclear magnetism, mass spectrum and element analysis, the result shows that the structure is correct, and the data is as follows:
nuclear magnetism1H NMR(400MHz,CDCl3):2.25(t,2H),3.15(t,2H),3.81(t,2H),3.84(t,2H),4.31-4.35(m,4H),4.44(s,2H),6.97(d,2H),7.04-7.06(m,2H),7.41(d,1H),7.51-7.54(m,2H)。
Mass Spectrometry ESI-MS:495.17([ M + Na ]]+)。
Elemental analysis anal.calcd for C22H21ClN4O4S:C,55.87;H,4.48;N,11.85.Found:C,56.09;H,4.46;N,11.90%。
Example 5
Preparation of 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (2-fluorophenyl) piperazine) ethanone of the formula:
Figure BDA0001574407100000062
the o-methoxyphenylpiperazine of example 1 was changed to o-fluorophenylpiperazine, and the remaining steps were the same as in example 1, to give 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (4- (2-fluorophenyl) piperazine) ethanone.
The compound is verified by nuclear magnetism, mass spectrum and element analysis, the result shows that the structure is correct, and the data is as follows:
nuclear magnetism1H NMR(400MHz,CDCl3):3.12(t,2H),3.19(t,2H),3.81(t,2H),3.88(t,2H),4.29-4.34(m,4H),4.41(s,2H),6.14-7.12(m,5H),7.49-7.52(m,2H)。
Mass Spectrometry ESI-MS:479.33([ M + Na ]]+)
Elemental analysis anal.calcd for C22H21FN4O4S:C,57.88;H,4.64;N,12.27.Found:C,58.05;H,4.62;N,12.31%。
Example 6
Preparation of 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (2-pyridylpiperazine) ethanone of the formula:
Figure BDA0001574407100000071
the intermediate methoxyphenylpiperazine of example 2 was changed to 2-pyridylpiperazine, and the remaining steps were the same as in example 2 to give 2- (5- (2, 3-dihydrobenzo [1,4] dioxane) -1,3, 4-oxadiazole-2-thione) -1- (2-pyridylpiperazine) ethanone.
The compound is verified by nuclear magnetism, mass spectrum and element analysis, the result shows that the structure is correct, and the data is as follows:
nuclear magnetism1H NMR(400MHz,CDCl3):3.49(s,2H),3.75(s,4H),3.82(s,2H),4.35-4.33(m,4H),4.40(s,2H),6.70(m,2H),6.95(d,2H),7.51(m,3H)。
Mass Spectrometry ESI-MS:901.17([2M + Na)]+)。
Elemental analysis anal.calcd for C21H21N5O4S:C,57.39;H,4.82;N,15.94.Found:C,57.60;H,4.80;N,115.97%。
The properties, yield and melting point data of the piperazine amide compounds containing benzodioxane skeleton in examples 1 to 6 are shown in table 1.
TABLE 1 data sheet
Serial number Traits Yield (%) Melting Point (. degree.C.)
Example 1 White powder 75.5 171.0-172.5
Example 2 White powder 78.3 158.6-159.0
Example 3 White powder 76.3 197.1-198.3
Example 4 Brown powder 65.2 173.4-174.6
Example 5 Brown powder 82.3 154.1-155.5
Example 6 Brown powder 82.3 156.2-157.0
Example 7
The anti-inflammatory activity of the piperazine amide compounds containing benzodioxane skeletons in examples 1 to 6 was examined by the following specific steps:
18-22 g of KM mice were adaptively maintained for one week and randomly divided into a blank control group, a positive control group and an experimental group, each group consisting of 7 mice, all the mice were fasted without water for 20 hours before the experiment, the mice in the blank control group, the positive control group and the experimental group were administered with physiological saline, diclofenac sodium and the piperazine amide compound containing a benzodioxane skeleton of examples 1-6, respectively, by gavage, after 1 hour of gavage, 40. mu.l of xylene was evenly applied to both sides of the right ear of the mice to cause inflammation, the left ear was not treated, after 1 hour, the mice were decapped, both ears were cut, the ear pieces of the same part of both ears were punched out with a punch, and the mice were weighed on an analytical balance, and the difference between the left and right ear pieces of the same mice was used as a swelling value (average swelling value of the blank control group-average swelling value of the administration group)/average swelling value of the blank control group × 100%, and the data are shown in Table 2.
TABLE 2 anti-inflammatory Activity test results for examples 1-6, positive control and blank control
Serial number Swelling number (mg) Swelling inhibition ratio (%)
Example 1 4.34±0.24 68.02
Example 2 6.81±0.54 49.82
Example 3 5.83±0.74 57.04
Example 4 6.36±0.45 59.15
Example 5 6.79±0.70 49.96
Example 6 7.36±1.31 45.76
Positive control group 6.51±0.95 52.03
Blank control group 13.57±1.09

Claims (10)

1. A piperazine amide compound containing benzodioxane skeleton is characterized in that the structural formula is as follows:
Figure 643568DEST_PATH_IMAGE001
wherein R is one of the following structures:
Figure 354035DEST_PATH_IMAGE002
performing cyclization reaction on the 1, 4-benzodioxan formyl hydrazine and carbon disulfide to obtain a benzodioxan sulfydryl derivative;
carrying out nucleophilic substitution reaction on acyl chloride with higher activity in chloroacetyl chloride and unsubstituted amino in the monosubstituted piperazine derivative to obtain a piperazine amide intermediate;
α -chlorine in the piperazine amide intermediate and mercapto in the benzodioxan mercapto derivative are subjected to nucleophilic substitution reaction to obtain the piperazine amide compound containing the benzodioxan skeleton.
2. A method for producing a piperazine amide compound containing a benzodioxane skeleton according to claim 1, comprising the steps of:
(1) mixing 1, 4-benzodioxan formyl hydrazine, potassium hydroxide and methanol, dripping carbon disulfide in an ice-water bath, performing reflux reaction, spin-drying a solvent, adding water, filtering, and acidifying filtrate to obtain a product a;
(2) mixing a substitute of piperazine, triethylamine and dichloromethane, dropwise adding chloroacetyl chloride in an ice water bath, reacting, and filtering to obtain a product b;
(3) and mixing the product a, the product b, potassium hydroxide and methanol, and reacting to obtain the piperazine amide compound containing the benzodioxane skeleton.
3. The method for producing a piperazine amide compound having a benzodioxane skeleton according to claim 2, wherein: in the step (1), the dosage ratio of the 1, 4-benzodioxan formyl hydrazine, the potassium hydroxide, the carbon disulfide and the methanol is 1:1.2-1.5:10:5-7, wherein the 1, 4-benzodioxan formyl hydrazine, the potassium hydroxide and the carbon disulfide are calculated by millimole, and the methanol is calculated by milliliter.
4. The method for producing a piperazine amide compound having a benzodioxane skeleton according to claim 2, wherein: in the step (1), the dropping time of the carbon disulfide is 15-20 minutes.
5. The method for producing a piperazine amide compound having a benzodioxane skeleton according to claim 2, wherein: in the step (1), the reflux reaction time is 8-10 hours.
6. The method for producing a piperazine amide compound having a benzodioxane skeleton according to claim 2, wherein: in the step (2), the dosage ratio of the substituent of piperazine, chloracetyl chloride, triethylamine and dichloromethane is 1:1.2-1.5:1.2-1.5:4, wherein the substituent of piperazine, chloracetyl chloride and triethylamine are calculated by millimole, and the dichloromethane is calculated by milliliter.
7. The method for producing a piperazine amide compound having a benzodioxane skeleton according to claim 2, wherein: in the step (2), the substitute of piperazine is one of o-methoxyphenylpiperazine, m-methoxyphenylpiperazine, p-methoxyphenylpiperazine, o-chlorophenylpiperazine, m-chlorophenylpiperazine, o-fluorophenylpiperazine, 2-pyridylpiperazine or m-trifluoromethylphenylpiperazine.
8. The method for producing a piperazine amide compound having a benzodioxane skeleton according to claim 2, wherein: in the step (2), the dripping time of the chloracetyl chloride is 3-5 minutes; the reaction time is 10-12 hours.
9. The method for producing a piperazine amide compound having a benzodioxane skeleton according to claim 2, wherein: in the step (3), the using amount ratio of the product a to the product b to the potassium hydroxide to the methanol is 1:1:1.5:8, wherein the product a, the product b and the potassium hydroxide are calculated by millimoles, and the methanol is calculated by milliliters; the reaction time is 4-6 hours.
10. The use of the benzodioxane skeleton-containing piperazine amide compound according to claim 1, wherein: is used for preparing the non-steroidal anti-inflammatory drug.
CN201810129153.4A 2018-02-08 2018-02-08 Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof Active CN108341807B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810129153.4A CN108341807B (en) 2018-02-08 2018-02-08 Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810129153.4A CN108341807B (en) 2018-02-08 2018-02-08 Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN108341807A CN108341807A (en) 2018-07-31
CN108341807B true CN108341807B (en) 2020-07-28

Family

ID=62958730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810129153.4A Active CN108341807B (en) 2018-02-08 2018-02-08 Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN108341807B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114751868B (en) * 2022-04-22 2024-04-12 山东理工大学 Diaryl substituted triazole acetic acid compound, and preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271045T1 (en) * 1998-09-03 2004-07-15 Kyowa Hakko Kogyo Kk OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS
CN102690261B (en) * 2011-03-25 2015-02-25 南京大学 Preparation method of 1,4-benzodioxan-containing 1,3,4-oxadiazole derivatives and use of the 1,4-benzdioxan-containing 1,3,4-oxadiazole derivatives in anti-cancer drugs
CN103087053A (en) * 2011-11-03 2013-05-08 南京大学 Preparation of oxadiazole compound and application thereof to anti-inflammatory treatment
CN103382204B (en) * 2013-04-07 2016-03-23 南京农业大学 Containing the preparation method and its usage of 1,3,4-oxadiazole derivative of benzo Isosorbide-5-Nitrae-Evil dioxane
CN104292224B (en) * 2014-09-24 2016-07-06 贵州大学 Containing replacing 1,3,4-thiophene () diazole thioether benzothiazole amide derivatives and its preparation method and application
CN105777731B (en) * 2016-04-22 2018-10-16 山东理工大学 The bridged piperazine derivatives and its preparation method and application of Han You oxadiazoles

Also Published As

Publication number Publication date
CN108341807A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
EP3920918A1 (en) Methods and compositions for modulating splicing
CN107033087B (en) 1H-indazole-4-amine compounds and use thereof as IDO inhibitors
WO2020163544A1 (en) Methods and compositions for modulating splicing
JP2022521467A (en) Methods and compositions for regulating splicing
CN104557588B (en) Caffeic acid and the homodimer of ferulic acid, its preparation method and pharmaceutical composition thereof
CN101289481A (en) Synthesis of N-aryl-3-(4-beta-D-allopyranoside phenyl)-5-formyl isoxazole-4-methane amide
JP2012514018A (en) Toluidine sulfonamides and their use
JP2012514019A (en) Toluidinesulfonamides and their use as inhibitors
CN104592195A (en) A preparing process of alogliptin benzoate
CN108341807B (en) Piperazine amide compound containing benzodioxane skeleton and preparation method and application thereof
CN104080335B (en) Some chemical entities, composition and method
CN111018738B (en) Paeonol derivative, pharmaceutical preparation, preparation method and application
TWI834819B (en) Methods of making high enantioselective secondary alcohols
CN108358928A (en) A kind of preparation method of (6S) -5-methyltetrahydrofolate calcium
WO2004087164A1 (en) 8-nitro-tryptanthrin and other tryptanthrin derivatives used for the treatment of diseases caused by highly proliferating cells
CN116284018A (en) Preparation method and application of furo [2,3-b ] quinoline derivative
CN113493374B (en) SIRT1 receptor agonist and medicine containing same
CN102060875B (en) Quinazoline derivative, and preparation method and application thereof
CN102875499B (en) The preparation method of 3-aminomethyl trimethylene oxide and organic acid salt thereof
CN100567304C (en) Methylsulfonic acid 10-O-(dimethyl amido ethyl) Ginkgolide B semihydrate crystal and preparation method thereof
CN115710253B (en) Aminobenzimidazole-containing derivatives, and preparation and application thereof
WO2014046224A1 (en) Coumarin derivative
CN113277980B (en) Tolvaptan impurity and preparation method thereof
JPH02502728A (en) N-naphthoylglycine as an aldose reductase inhibitor
TW201245197A (en) Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant